Literature DB >> 12023816

Role of Src in signal transduction pathways. The Jubilee Lecture.

Sara A Courtneidge1.   

Abstract

Src was the first oncogene to be discovered, and the first protein tyrosine kinase. The study of how Src transforms cells has been a rich field that has lead to insights into the control of the cell cycle, the organization of the cytoskeleton, and growth factor-independent growth. Yet we still do not fully understand exactly what Src does. In normal cells, Src has been implicated in the control of cell division, the production of autocrine growth factors, the cell's survival response, as well as in cell motility. My laboratory has focused on the involvement of Src and related kinases in the response of cells to mitogenic growth factors. We have shown that the activity of Src kinases is necessary for cells to enter the cell cycle when treated with mitogens such as platelet-derived growth factor. Src activity initiates a signal transduction cascade, involving the adaptor protein Shc, which culminates in the transcriptional activation of the transcription factor Myc. Furthermore, we have also shown that this requirement for Src is abrogated in cells lacking the tumour suppressor p53, suggesting that another of Src's functions in normal cells is to suppress the actions of p53.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023816     DOI: 10.1042/

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  21 in total

1.  RACK1 regulates G1/S progression by suppressing Src kinase activity.

Authors:  Vidya Mamidipudi; Jian Zhang; Kelly C Lee; Christine A Cartwright
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

2.  The P2Y2 receptor mediates the epithelial injury response and cell migration.

Authors:  Ilene Boucher; Celeste Rich; Albert Lee; Meredith Marcincin; Vickery Trinkaus-Randall
Journal:  Am J Physiol Cell Physiol       Date:  2010-04-28       Impact factor: 4.249

Review 3.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

4.  Combinatory action of VEGFR2 and MAP kinase pathways maintains endothelial-cell integrity.

Authors:  Hanbing Zhong; Danyang Wang; Nan Wang; Yesenia Rios; Haigen Huang; Song Li; Xinrong Wu; Shuo Lin
Journal:  Cell Res       Date:  2011-03-22       Impact factor: 25.617

5.  Localized activation of Src-family protein kinases in the mouse egg.

Authors:  Lynda K McGinnis; David F Albertini; William H Kinsey
Journal:  Dev Biol       Date:  2007-03-24       Impact factor: 3.582

Review 6.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

7.  The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.

Authors:  C H Benes; G Poulogiannis; L C Cantley; S P Soltoff
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

8.  New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.

Authors:  Alessandra Rossi; Silvia Schenone; Adriano Angelucci; Martina Cozzi; Valentina Caracciolo; Francesca Pentimalli; Andrew Puca; Biagio Pucci; Raffaele La Montagna; Mauro Bologna; Maurizio Botta; Antonio Giordano
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

9.  Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells.

Authors:  Melodie L Knowlton; Laura M Selfors; Carolyn N Wrobel; Ting-Lei Gu; Bryan A Ballif; Steven P Gygi; Roberto Polakiewicz; Joan S Brugge
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

10.  Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

Authors:  June G Lee; Rong Zheng; Jennifer M McCafferty-Cepero; Kerry L Burnstein; David M Nanus; Ruoqian Shen
Journal:  Mol Carcinog       Date:  2009-02       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.